PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Post-LOEglimepiride; pioglitazone hydrochloride
ANDAORALTABLET
Approved
Jan 2013
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE (glimepiride; pioglitazone hydrochloride) by Molecular Devices is cells. First approved in 2013.
Drug data last refreshed 19h ago
Mechanism of Action
cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.